Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer (Nature Communications, (2022), 13, 1, (5258), 10.1038/s41467-022-32828-6)

Marta Palafox; Laia Monserrat; Meritxell Bellet; Guillermo Villacampa; Abel Gonzalez-Perez; Mafalda Oliveira; Fara Brasó-Maristany; Nusaibah Ibrahimi; Srinivasaraghavan Kannan; Leonardo Mina; Maria Teresa Herrera-Abreu; Andreu Òdena; Mònica Sánchez-Guixé; Marta Capelán; Analía Azaro; Alejandra Bruna; Olga Rodríguez; Marta Guzmán; Judit Grueso; Cristina Viaplana; Javier Hernández; Faye Su; Kui Lin; Robert B. Clarke; Carlos Caldas; Joaquín Arribas; Stefan Michiels; Alicia García-Sanz; Nicholas C. Turner; Aleix Prat; Paolo Nuciforo; Rodrigo Dienstmann; Chandra S. Verma; Nuria Lopez-Bigas; Maurizio Scaltriti; Monica Arnedos; Cristina Saura; Violeta Serra

doi:10.1038/s41467-022-34580-3

Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER⁺ breast cancer (Nature Communications, (2022), 13, 1, (5258), 10.1038/s41467-022-32828-6)

Marta Palafox, Laia Monserrat, Meritxell Bellet, Guillermo Villacampa, Abel Gonzalez-Perez, Mafalda Oliveira, Fara Brasó-Maristany, Nusaibah Ibrahimi, Srinivasaraghavan Kannan, Leonardo Mina, Maria Teresa Herrera-Abreu, Andreu Òdena, Mònica Sánchez-Guixé, Marta Capelán, Analía Azaro, Alejandra Bruna, Olga Rodríguez, Marta Guzmán, Judit Grueso, Cristina ViaplanaJavier Hernández, Faye Su, Kui Lin, Robert B. Clarke, Carlos Caldas, Joaquín Arribas, Stefan Michiels, Alicia García-Sanz, Nicholas C. Turner, Aleix Prat, Paolo Nuciforo, Rodrigo Dienstmann, Chandra S. Verma, Nuria Lopez-Bigas, Maurizio Scaltriti, Monica Arnedos, Cristina Saura, Violeta Serra

Research output: Contribution to journal › Comment/debate

Abstract

The original version of the Supplementary Information associated with this Article included an incorrect Supplementary Information file, inwhich tracked changes fromrevision werepresent. The HTML has been updated to include a corrected version of the Supplementary Information; the original incorrect version can be found as Supplementary Information associated with this Correction. In the original version of the published article, the Acknowledgements section omitted a grant number. The correct Acknowledgements paragraph includes the following: This study has been supported by the Susan G. Komen Foundation (CCR15330331) and by the Catalan Agency AGAUR (2017 SGR 540). This has now been corrected both in the HTML and the PDF versions of the article.

Original language	English
Article number	6928
Journal	Nature Communications
Volume	13
Issue number	1
DOIs	https://doi.org/10.1038/s41467-022-34580-3
Publication status	Published - 1 Dec 2022

Access to Document

10.1038/s41467-022-34580-3

Cite this

Palafox, M., Monserrat, L., Bellet, M., Villacampa, G., Gonzalez-Perez, A., Oliveira, M., Brasó-Maristany, F., Ibrahimi, N., Kannan, S., Mina, L., Herrera-Abreu, M. T., Òdena, A., Sánchez-Guixé, M., Capelán, M., Azaro, A., Bruna, A., Rodríguez, O., Guzmán, M., Grueso, J., ... Serra, V. (2022). Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER⁺ breast cancer (Nature Communications, (2022), 13, 1, (5258), 10.1038/s41467-022-32828-6). Nature Communications, 13(1), Article 6928. https://doi.org/10.1038/s41467-022-34580-3

@article{ea52098231bb4967b9b81536fb8a8fe6,

title = "Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer (Nature Communications, (2022), 13, 1, (5258), 10.1038/s41467-022-32828-6)",

abstract = "The original version of the Supplementary Information associated with this Article included an incorrect Supplementary Information file, inwhich tracked changes fromrevision werepresent. The HTML has been updated to include a corrected version of the Supplementary Information; the original incorrect version can be found as Supplementary Information associated with this Correction. In the original version of the published article, the Acknowledgements section omitted a grant number. The correct Acknowledgements paragraph includes the following: This study has been supported by the Susan G. Komen Foundation (CCR15330331) and by the Catalan Agency AGAUR (2017 SGR 540). This has now been corrected both in the HTML and the PDF versions of the article.",

author = "Marta Palafox and Laia Monserrat and Meritxell Bellet and Guillermo Villacampa and Abel Gonzalez-Perez and Mafalda Oliveira and Fara Bras{\'o}-Maristany and Nusaibah Ibrahimi and Srinivasaraghavan Kannan and Leonardo Mina and Herrera-Abreu, {Maria Teresa} and Andreu {\`O}dena and M{\`o}nica S{\'a}nchez-Guix{\'e} and Marta Capel{\'a}n and Anal{\'i}a Azaro and Alejandra Bruna and Olga Rodr{\'i}guez and Marta Guzm{\'a}n and Judit Grueso and Cristina Viaplana and Javier Hern{\'a}ndez and Faye Su and Kui Lin and Clarke, {Robert B.} and Carlos Caldas and Joaqu{\'i}n Arribas and Stefan Michiels and Alicia Garc{\'i}a-Sanz and Turner, {Nicholas C.} and Aleix Prat and Paolo Nuciforo and Rodrigo Dienstmann and Verma, {Chandra S.} and Nuria Lopez-Bigas and Maurizio Scaltriti and Monica Arnedos and Cristina Saura and Violeta Serra",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2022.",

year = "2022",

month = dec,

day = "1",

doi = "10.1038/s41467-022-34580-3",

language = "English",

volume = "13",

journal = "Nature Communications",

issn = "2041-1723",

number = "1",

}

Palafox, M, Monserrat, L, Bellet, M, Villacampa, G, Gonzalez-Perez, A, Oliveira, M, Brasó-Maristany, F, Ibrahimi, N, Kannan, S, Mina, L, Herrera-Abreu, MT, Òdena, A, Sánchez-Guixé, M, Capelán, M, Azaro, A, Bruna, A, Rodríguez, O, Guzmán, M, Grueso, J, Viaplana, C, Hernández, J, Su, F, Lin, K, Clarke, RB, Caldas, C, Arribas, J, Michiels, S, García-Sanz, A, Turner, NC, Prat, A, Nuciforo, P, Dienstmann, R, Verma, CS, Lopez-Bigas, N, Scaltriti, M, Arnedos, M, Saura, C & Serra, V 2022, 'Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER⁺ breast cancer (Nature Communications, (2022), 13, 1, (5258), 10.1038/s41467-022-32828-6)', Nature Communications, vol. 13, no. 1, 6928. https://doi.org/10.1038/s41467-022-34580-3

Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER⁺ breast cancer (Nature Communications, (2022), 13, 1, (5258), 10.1038/s41467-022-32828-6). / Palafox, Marta; Monserrat, Laia; Bellet, Meritxell et al.
In: Nature Communications, Vol. 13, No. 1, 6928, 01.12.2022.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Author Correction

T2 - High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer (Nature Communications, (2022), 13, 1, (5258), 10.1038/s41467-022-32828-6)

AU - Palafox, Marta

AU - Monserrat, Laia

AU - Bellet, Meritxell

AU - Villacampa, Guillermo

AU - Gonzalez-Perez, Abel

AU - Oliveira, Mafalda

AU - Brasó-Maristany, Fara

AU - Ibrahimi, Nusaibah

AU - Kannan, Srinivasaraghavan

AU - Mina, Leonardo

AU - Herrera-Abreu, Maria Teresa

AU - Òdena, Andreu

AU - Sánchez-Guixé, Mònica

AU - Capelán, Marta

AU - Azaro, Analía

AU - Bruna, Alejandra

AU - Rodríguez, Olga

AU - Guzmán, Marta

AU - Grueso, Judit

AU - Viaplana, Cristina

AU - Hernández, Javier

AU - Su, Faye

AU - Lin, Kui

AU - Clarke, Robert B.

AU - Caldas, Carlos

AU - Arribas, Joaquín

AU - Michiels, Stefan

AU - García-Sanz, Alicia

AU - Turner, Nicholas C.

AU - Prat, Aleix

AU - Nuciforo, Paolo

AU - Dienstmann, Rodrigo

AU - Verma, Chandra S.

AU - Lopez-Bigas, Nuria

AU - Scaltriti, Maurizio

AU - Arnedos, Monica

AU - Saura, Cristina

AU - Serra, Violeta

PY - 2022/12/1

Y1 - 2022/12/1

N2 - The original version of the Supplementary Information associated with this Article included an incorrect Supplementary Information file, inwhich tracked changes fromrevision werepresent. The HTML has been updated to include a corrected version of the Supplementary Information; the original incorrect version can be found as Supplementary Information associated with this Correction. In the original version of the published article, the Acknowledgements section omitted a grant number. The correct Acknowledgements paragraph includes the following: This study has been supported by the Susan G. Komen Foundation (CCR15330331) and by the Catalan Agency AGAUR (2017 SGR 540). This has now been corrected both in the HTML and the PDF versions of the article.

AB - The original version of the Supplementary Information associated with this Article included an incorrect Supplementary Information file, inwhich tracked changes fromrevision werepresent. The HTML has been updated to include a corrected version of the Supplementary Information; the original incorrect version can be found as Supplementary Information associated with this Correction. In the original version of the published article, the Acknowledgements section omitted a grant number. The correct Acknowledgements paragraph includes the following: This study has been supported by the Susan G. Komen Foundation (CCR15330331) and by the Catalan Agency AGAUR (2017 SGR 540). This has now been corrected both in the HTML and the PDF versions of the article.

UR - http://www.scopus.com/inward/record.url?scp=85141821929&partnerID=8YFLogxK

U2 - 10.1038/s41467-022-34580-3

DO - 10.1038/s41467-022-34580-3

M3 - Comment/debate

C2 - 36376284

AN - SCOPUS:85141821929

SN - 2041-1723

VL - 13

JO - Nature Communications

JF - Nature Communications

IS - 1

M1 - 6928

ER -

Palafox M, Monserrat L, Bellet M, Villacampa G, Gonzalez-Perez A, Oliveira M et al. Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER⁺ breast cancer (Nature Communications, (2022), 13, 1, (5258), 10.1038/s41467-022-32828-6). Nature Communications. 2022 Dec 1;13(1):6928. doi: 10.1038/s41467-022-34580-3

Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer (Nature Communications, (2022), 13, 1, (5258), 10.1038/s41467-022-32828-6)

Abstract

Access to Document

Other files and links

Cite this

Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER⁺ breast cancer (Nature Communications, (2022), 13, 1, (5258), 10.1038/s41467-022-32828-6)